Thank you very much, and again my apologies that we're not going to have the time available to us to pay attention to all the important issues you have brought before us.
I want to go back to the IP issue on pharmaceuticals. It is important that you understand that when we raise the issues about the $2.8 billion, we're not against innovation. We're not against the work that the brand-name pharmaceuticals do. By no stretch of the imagination is that the case.
However, what I want to know is how are my province of Nova Scotia, this country, and the people in it going to absorb an extra $2.8 billion? If that's not going to happen, then somebody tell me that. Give me some facts to contradict that or tell me that the benefits brought on by the investments by the brand names are going to offset that. I have not heard any of that in this debate. I've talked to the government; I've talked to some of your representatives, and my constituents and other people across this country are concerned about the impact this is going to have on our health care system.
I want to get right down to what we are talking about in terms of cost here, please. I say that with the greatest respect.